4T1 Cell Membrane Biomimetic Nanovehicle for Enhanced Breast Cancer Treatment

被引:0
|
作者
Liu, Mengkang [1 ]
Sun, Yufeng [1 ]
Wei, Qiuxian [1 ]
Zhang, Anna [1 ]
Wang, Saifei [1 ]
Wang, Dan [1 ]
Dong, Zhipeng [1 ]
Ma, Xiaonan [2 ]
Yan, Ran [1 ]
Wang, Yue [1 ]
机构
[1] China Pharmaceut Univ, Sch Sci, Key Lab Biomed Funct Mat, Nanjing 211198, Peoples R China
[2] China Pharmaceut Univ, Publ Lab Platform, Nanjing 211198, Peoples R China
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2024年 / 16卷 / 01期
关键词
Mesoporous silica; Cell membrane biomimetic; Homologous targeting; Immune escape; Breast cancer; CAMOUFLAGED NANOPARTICLES; COATED NANOPARTICLES; PLATFORM; DELIVERY;
D O I
10.1021/acsmedchemlett.4c00425
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this study, hollow mesoporous silica nanoparticles (HMSN) coated with a 4T1 tumor cell membrane were used to construct biomimetic nanomaterials (DTX@CHMSN) for the treatment of breast cancer. The nanodrug can improve the water solubility of polyenetaxel (DTX) by taking advantage of the special structure, good biocompatibility, and adjustable surface chemical properties of HMSN. Hollow mesoporous silica nanoparticles are coated with 4T1 cell membranes derived from homologous tumors (CHMSN). Adhesion glycoproteins on cancer cell membranes specifically bind to receptors on the cell membranes of the same cancer cell to target specific breast cancer tissues. At the same time, the cell membrane of the 4T1 tumor also contains CD47 protein, which can be specifically recognized by the immune system to produce immune escape. Therefore, the biomimetic nanomedicine DTX@CHMSN, with homologous targeting and immune escape ability, can accumulate in large quantities at the tumor site, reduce systemic toxicity, and thus improve the therapeutic effect.
引用
收藏
页码:51 / 58
页数:8
相关论文
共 50 条
  • [1] Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion
    Filatenkov, Alexander
    Baker, Jeanette
    Muller, Antonia M.
    Ahn, G-One
    Kohrt, Holbrook
    Dutt, Suparna
    Jansen, Kent
    Dejbakhsh-Jones, Sussan
    Negrin, Robert S.
    Shizuru, Judith A.
    Engleman, Edgar G.
    Strober, Samuel
    RADIATION RESEARCH, 2014, 182 (02) : 163 - 169
  • [2] The cytotoxicity and apoptotic effects of verbascoside on breast cancer 4T1 cell line
    Atena Daneshforouz
    Samad Nazemi
    Omid Gholami
    Marzieh Kafami
    Bahareh Amin
    BMC Pharmacology and Toxicology, 22
  • [3] The cytotoxicity and apoptotic effects of verbascoside on breast cancer 4T1 cell line
    Daneshforouz, Atena
    Nazemi, Samad
    Gholami, Omid
    Kafami, Marzieh
    Amin, Bahareh
    BMC PHARMACOLOGY & TOXICOLOGY, 2021, 22 (01):
  • [4] Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A
    Izgia, Kenan
    Iskender, Banu
    Sakalar, Cagri
    Arslanhan, Aslihan
    Yuksek, Esra Hilal
    Hizar, Esra
    Canatan, Halit
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (03) : 404 - 414
  • [5] Eupatorin Suppressed Tumor Progression and Enhanced Immunity in a 4T1 Murine Breast Cancer Model
    Abd Razak, Nursyamirah
    Yeap, Swee Keong
    Alitheen, Noorjahan Banu
    Ho, Wan Yong
    Yong, Chean Yeah
    Tan, Sheau Wei
    Tan, Wen Siang
    Long, Kamariah
    INTEGRATIVE CANCER THERAPIES, 2020, 19
  • [6] Anticancer tendency of aflatoxin B1 in 4T1 breast cancer cell line
    Mousazadeh, Roya
    Hesaraki, Saeed
    Bayat, Mansour
    Jahandideh, Alireza
    Hashemi, Jamal
    GENE REPORTS, 2019, 16
  • [7] The Effect of Lidocaine and Bosutinib on 4T1 Murine Breast Cancer Cell Behaviour In Vitro
    Wall, Thomas P.
    Crowley, Peter D.
    Buggy, Donal J.
    ANTICANCER RESEARCH, 2021, 41 (06) : 2835 - 2840
  • [8] A transcriptional repressor of osteopontin expression in the 4T1 murine breast cancer cell line
    Gao, CJ
    Mi, ZY
    Guo, HT
    Wei, JP
    Wai, PY
    Kuo, PC
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 321 (04) : 1010 - 1016
  • [9] Neuropeptide Y stimulates proliferation and migration in the 4T1 breast cancer cell line
    Medeiros, Philip J.
    Al-Khazraji, Baraa K.
    Novielli, Nicole M.
    Postovit, Lynne M.
    Chambers, Ann F.
    Jackson, Dwayne N.
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (02) : 276 - 286
  • [10] Disease progression model of 4T1 metastatic breast cancer
    Liang Yang
    Ling Yong
    Xiao Zhu
    Yaoyao Feng
    Yu Fu
    Daming Kong
    Wei Lu
    Tian-yan Zhou
    Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47 : 105 - 116